MATTERHORN: perioperative durvalumab with FLOT chemotherapy for resectable gastric and gastro-oesophageal junction cancer
Adding durvalumab to perioperative FLOT chemotherapy for operable stomach cancer reduced recurrences and doubled the rate of complete pathological response, the first immunotherapy to improve outcomes in curable gastric cancer.
Overview
Phase 3 placebo-controlled trial of 948 patients with resectable stage II to IVA gastric or gastro-oesophageal junction adenocarcinoma randomised to perioperative FLOT with durvalumab or placebo, followed by durvalumab or placebo maintenance.
Event-free survival at 24 months was 67.4 versus 58.5 percent (hazard ratio 0.71), pathological complete response 19 versus 7 percent, and an interim overall survival analysis favoured durvalumab; surgery rates and toxicity were similar between arms.
- 24-month event-free survival 67.4 percent vs 58.5 percent; hazard ratio 0.71.
- Pathological complete response 19 percent vs 7 percent.
Perioperative durvalumab with FLOT is a new standard for resectable gastric and junctional adenocarcinoma irrespective of PD-L1 expression.
- Overall survival analysis interim.
- Applicability to Asian populations receiving adjuvant-only chemotherapy is uncertain.
Similar pages
not linked directly; found by shared links- Key paperADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer
- Key paperPACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer
- Key paperNIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer
- TreatmentFLOT (5-FU, leucovorin, oxaliplatin, docetaxel)
Shares MATTERHORN, PD-L1-high gastric cancer.